The Optimization of HL60-IL6 Assay and its Application in the Pyrogen Detection of Monoclonal Antibody

Author(s): Mingren Wang, Shanshan Dong, Hong Shao, Can Wang*, Gang Chen*

Journal Name: Current Pharmaceutical Analysis

Volume 16 , Issue 3 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: The HL60-IL6 assay has been initially established, but the process of the assay and calculation was not simplified. And there are no reports on whether it can be applied to detect pyrogen contamination in the monoclonal antibody.

Objective: The study aimed to improve the HL60/IL-6 assay and detect the pyrogens in the monoclonal antibody drug by HL60-IL6 assay.

Methods: The human promyelocytic leukemia cell line (HL-60) was incubated with pyrogen standard solution, such as lipopolysaccharide (LPS), zymosan and lipoteichoic acid (LTA),or monoclonal antibody sample solution for 48 hours, and then cytokines interleukin-6 (IL-6),secreted from HL-60, were measured by ELISA. The study further described the standard curves on OD (Optical Density) value of IL-6 responding to pyrogen stimulation, and determined the content of pyrogen in the monoclonal antibody production after validation. In addition, the sensitivity of HL60 to three pyrogens was evaluated to establish one standard curve to determine endotoxin and non-endotoxin level. Then, the credibility of standard curves was evaluated. After improvement of the assay, 9 monoclonal antibody batches were assayed for pyrogens in parallel with the Rabbit Pyrogen Test (RPT) and HL60/IL-6 assay.

Results: It was achieved that the standard curve between OD value of IL-6 and pyrogen concentration was established. Then, it was found that the sensitivity of HL60 responding to LPS was the weakest, as a result of which, only LPS standard curve needs to be described in each test for detection of pyrogens. Besides, to evaluate the credibility of standard curve, the parameters of the standard curve were restricted and the resulting interpretation was also specified. 3 Bevacizumab batches failed the RPT, which also showed pyrogenic contamination by the HL60/IL-6 assay.

Conclusion: HL60-IL6 assay was improved and can be applied to pyrogen detection of monoclonal antibody.

Keywords: HL60-IL6 assay, pyrogen, monoclonal antibody, lipopolysaccharide, zymosan, lipoteichoic acid.

[1]
Dinarello, C.A.; O’Connor, J.V.; LoPreste, G.; Swift, R.L. Human leukocytic pyrogen test for detection of pyrogenic material in growth hormone produced by recombinant Escherichia coli. J. Clin. Microbiol., 1984, 20(3), 323-329.
[http://dx.doi.org/10.1128/JCM.20.3.323-329.1984] [PMID: 6386853]
[2]
Siddiqui, M.R.; AlOthman, Z.A.; Rahman, N. Analytical techniques in pharmaceutical analysis: a review. Arab. J. Chem., 2017, 10, S1409-S1421.
[http://dx.doi.org/10.1016/j.arabjc.2013.04.016]
[3]
Rahman, N.; Azmi, S.N.H.; Wu, H.F. The importance of impurity analysis in pharmaceutical products: an integrated approach. Accredit. Qual. Assur., 2006, 11, 69-74.
[http://dx.doi.org/10.1007/s00769-006-0095-y]
[4]
Hasiwa, M.; Kullmann, K.; von Aulock, S.; Klein, C.; Hartung, T. An in vitro pyrogen safety test for immune-stimulating components on surfaces. Biomaterials, 2007, 28(7), 1367-1375.
[http://dx.doi.org/10.1016/j.biomaterials.2006.11.016] [PMID: 17157907]
[5]
Ray, A.; Redhead, K.; Selkirk, S.; Poole, S. Variability in LPS composition, antigenicity and reactogenicity of phase variants of Bordetella pertussis. FEMS Microbiol. Lett., 1991, 63(2-3), 211-217.
[http://dx.doi.org/10.1111/j.1574-6968.1991.tb04531.x] [PMID: 2060761]
[6]
Taktak, Y.S.; Selkirk, S.; Bristow, A.F.; Carpenter, A.; Ball, C.; Rafferty, B.; Poole, S. Assay of pyrogens by interleukin-6 release from monocytic cell lines. J. Pharm. Pharmacol., 1991, 43(8), 578-582.
[http://dx.doi.org/10.1111/j.2042-7158.1991.tb03540.x] [PMID: 1681074]
[7]
Burger-Kentischer, A.; Abele, I.S.; Finkelmeier, D.; Wiesmüller, K.H.; Rupp, S. A new cell-based innate immune receptor assay for the examination of receptor activity, ligand specificity, signalling pathways and the detection of pyrogens. J. Immunol. Methods, 2010, 358(1-2), 93-103.
[http://dx.doi.org/10.1016/j.jim.2010.03.020] [PMID: 20385141]
[8]
Koryakina, A.; Frey, E.; Bruegger, P. Cryopreservation of human monocytes for pharmacopeial monocyte activation test. J. Immunol. Methods, 2014, 405, 181-191.
[http://dx.doi.org/10.1016/j.jim.2014.01.005] [PMID: 24456627]
[9]
Schindler, S.; Asmus, S.; von Aulock, S.; Wendel, A.; Hartung, T.; Fennrich, S. Cryopreservation of human whole blood for pyrogenicity testing. J. Immunol. Methods, 2004, 294(1-2), 89-100.
[http://dx.doi.org/10.1016/j.jim.2004.08.019] [PMID: 15604019]
[10]
Hoffmann, S.; Peterbauer, A.; Schindler, S.; Fennrich, S.; Poole, S.; Mistry, Y.; Montag-Lessing, T.; Spreitzer, I.; Löschner, B.; van Aalderen, M.; Bos, R.; Gommer, M.; Nibbeling, R.; Werner-Felmayer, G.; Loitzl, P.; Jungi, T.; Brcic, M.; Brügger, P.; Frey, E.; Bowe, G.; Casado, J.; Coecke, S.; de Lange, J.; Mogster, B.; Naess, L.M.; Aaberge, I.S.; Wendel, A.; Hartung, T. International validation of novel pyrogen tests based on human monocytoid cells. J. Immunol. Methods, 2005, 298(1-2), 161-173.
[http://dx.doi.org/10.1016/j.jim.2005.01.010] [PMID: 15847806]
[11]
Wang, C.; Dong, S.; Zhao, H.; Wang, Z.; Zhou, Q.; Wu, L.; Shao, H.; Chen, G. A novel monocyte-based pyrogen test based on the mechanism of human fever reaction. Curr. Pharm. Anal., 2016, 12(3), 227-233.
[http://dx.doi.org/10.2174/1573412912666151211200203]
[12]
Dong, S.; Wang, C.; Zhou, Q.; Wu, L.; Shao, H.; Chen, G. The application of HL60-IL6 assay in the pyrogen detection of vaccine. China Pharmacist, 2016, (05), 870-873.
[13]
Gaines Das, R.E.; Brügger, P.; Patel, M.; Mistry, Y.; Poole, S. Monocyte activation test for pro-inflammatory and pyrogenic contaminants of parenteral drugs: test design and data analysis. J. Immunol. Methods, 2004, 288(1-2), 165-177.
[http://dx.doi.org/10.1016/j.jim.2004.03.002] [PMID: 15183094]
[14]
European Pharmacopoeia. 2017, 07.
[15]
Pharmacopoeia of The People’s Republic of China; , 2015, p. III. 1142.
[16]
Ryu, J.K.; Kim, S.J.; Rah, S.H.; Kang, J.I.; Jung, H.E.; Lee, D.; Lee, H.K.; Lee, J.O.; Park, B.S.; Yoon, T.Y.; Kim, H.M. Reconstruction of LPS transfer cascade reveals structural determinants within LBP, CD14, and TLR4-MD2 for efficient LPS recognition and transfer. Immunity, 2017, 46(1), 38-50.
[http://dx.doi.org/10.1016/j.immuni.2016.11.007] [PMID: 27986454]
[17]
Berglund, N.A.; Holdbrook, D.A.; Khalid, S.; Bond, P.J. The Structural Basis for Lipid a Recognition in the CD14 Innate Immune Co-Receptor. Biophys. J., 2015, 108(2)(Suppl. 1), 350a-351a.
[http://dx.doi.org/10.1016/j.bpj.2014.11.1920]
[18]
Perkins, N.D. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat. Rev. Mol. Cell Biol., 2007, 8(1), 49-62.
[http://dx.doi.org/10.1038/nrm2083] [PMID: 17183360]
[19]
Kluger, M.J. Fever: role of pyrogens and cryogens. Physiol. Rev., 1991, 71(1), 93-127.
[http://dx.doi.org/10.1152/physrev.1991.71.1.93] [PMID: 1986393]
[20]
Wang, M.; Wang, C.; Chen, G. Advances in toll-like receptor signaling pathway induced by pyrogens. China Pharmacist, 2018, 21(03), 480-484.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 3
Year: 2020
Published on: 30 March, 2020
Page: [319 - 327]
Pages: 9
DOI: 10.2174/1573412914666180627142302
Price: $65

Article Metrics

PDF: 18
HTML: 3
EPUB: 1
PRC: 1